Key takeaways
Uptravi (selexipag) and Letairis (ambrisentan) are both medications used to treat pulmonary arterial hypertension (PAH), but they work in different ways. Uptravi is a prostacyclin agonist that helps relax blood vessels in the lungs, making it easier for your heart to pump blood. It is taken twice a day, either as an oral tablet or as an intravenous injection. On the other hand, Letairis is an endothelin receptor antagonist that blocks a protein called endothelin to relax blood vessels. It is taken once a day and is available as a lower-cost generic. One major difference is that Letairis can cause severe harm to unborn babies, so it is only available through a special REMS program for people who can get pregnant. Uptravi does not have this restriction. Additionally, Uptravi can cause side effects like headache and diarrhea, while Letairis commonly causes swelling in the arms or legs.
